	US 12,433,878 B2
	Uses of bupivacaine multivesicular liposomes as stellate ganglion block
Roy Winston, Tampa, FL (US); Jared Ham, Severn, MD (US); and Jonathan Slonin, Palm City, FL (US)
Assigned to Pacira Pharmaceuticals, Inc., San Diego, CA (US)
Filed by Pacira Pharmaceuticals, Inc., San Diego, CA (US)
Filed on Feb. 21, 2023, as Appl. No. 18/171,831.
Claims priority of provisional application 63/313,691, filed on Feb. 24, 2022.
Prior Publication US 2023/0277516 A1, Sep. 7, 2023
Int. Cl. A61K 31/445 (2006.01); A61K 9/00 (2006.01); A61P 23/02 (2006.01)

CPC A61K 31/445 (2013.01) [A61K 9/0019 (2013.01); A61P 23/02 (2018.01)]

18 Claims

1. A method of treating a patient suffering from cardiac electrical storm, comprising:

identifying or selecting a patient who has suffered from or is at risk of suffering from cardiac electrical storm or one or more episodes of cardiac arrhythmia; and

administering a composition of bupivacaine multivesicular liposomes (MVLs) to one or more nerves of stellate ganglion of the patient, or an autonomic tissue area peripheral to the stellate ganglion, wherein the composition comprises about 20 mg to about 100 mg bupivacaine;

wherein the administering of bupivacaine MVLs provides relief of cardiac electrical storm for 2 weeks and up to 6 months, and temporarily reduces or interrupts sympathetic stimulation to the cardiovascular system for 2 weeks and up to 6 months.